Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KURA Kura Oncology	$8.45 +5.4%	$6.76	$5.41 ▼ $21.40	$733.89M	0.19	1.47 million shs	2.74 million shs
NRIX Nurix Therapeutics	$9.06 -1.6%	$10.87	$8.18 ▼ $29.56	$689.11M	2.1	859,633 shs	314,510 shs
SXTC China SXT Pharmaceuticals	$1.45 -1.7%	$1.60	$0.95 ▼ $7.84	$168.82M	1.35	1.76 million shs	127,237 shs
TBPH Theravance Biopharma	$13.61 -1.1%	$12.23	$7.88 ▼ $14.55	$685.85M	0.05	288,768 shs	196,458 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KURA Kura Oncology	-1.60%	+0.75%	+44.58%	+15.75%	-59.05%
NRIX Nurix Therapeutics	-5.15%	+0.99%	-6.50%	-27.16%	-60.75%
SXTC China SXT Pharmaceuticals	-10.61%	+3.87%	-5.51%	-24.36%	-66.76%
TBPH Theravance Biopharma	-1.15%	-0.58%	+19.44%	+29.69%	+72.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KURA Kura Oncology	$8.45 +5.4%	$6.76	$5.41 ▼ $21.40	$733.89M	0.19	1.47 million shs	2.74 million shs
NRIX Nurix Therapeutics	$9.06 -1.6%	$10.87	$8.18 ▼ $29.56	$689.11M	2.1	859,633 shs	314,510 shs
SXTC China SXT Pharmaceuticals	$1.45 -1.7%	$1.60	$0.95 ▼ $7.84	$168.82M	1.35	1.76 million shs	127,237 shs
TBPH Theravance Biopharma	$13.61 -1.1%	$12.23	$7.88 ▼ $14.55	$685.85M	0.05	288,768 shs	196,458 shs

A Guide To High-Short-Interest Stocks

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KURA Kura Oncology	-1.60%	+0.75%	+44.58%	+15.75%	-59.05%
NRIX Nurix Therapeutics	-5.15%	+0.99%	-6.50%	-27.16%	-60.75%
SXTC China SXT Pharmaceuticals	-10.61%	+3.87%	-5.51%	-24.36%	-66.76%
TBPH Theravance Biopharma	-1.15%	-0.58%	+19.44%	+29.69%	+72.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KURA Kura Oncology	2.80	Moderate Buy	$24.10	185.38% Upside
NRIX Nurix Therapeutics	2.88	Moderate Buy	$29.07	221.05% Upside
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A
TBPH Theravance Biopharma	3.50	Strong Buy	$21.33	56.71% Upside

Current Analyst Ratings Breakdown

Latest SXTC, TBPH, NRIX, and KURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2025	KURA Kura Oncology	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral
8/26/2025	NRIX Nurix Therapeutics	Baird R W Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/15/2025	TBPH Theravance Biopharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/11/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$28.00 ➝ $24.00
7/31/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$32.00 ➝ $30.00
7/15/2025	NRIX Nurix Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Equal Weight	$17.00 ➝ $16.00
7/14/2025	NRIX Nurix Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$36.00 ➝ $34.00
7/10/2025	NRIX Nurix Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$30.00 ➝ $26.00
7/10/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$32.00 ➝ $30.00
7/10/2025	NRIX Nurix Therapeutics	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$30.00
6/27/2025	TBPH Theravance Biopharma	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$24.00 ➝ $25.00

(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KURA Kura Oncology	$53.88M	13.60	N/A	N/A	$5.32 per share	1.59
NRIX Nurix Therapeutics	$88.38M	7.83	N/A	N/A	$7.44 per share	1.22
SXTC China SXT Pharmaceuticals	$1.74M	96.64	N/A	N/A	$21.35 per share	0.07
TBPH Theravance Biopharma	$64.38M	10.65	N/A	N/A	$3.57 per share	3.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KURA Kura Oncology	-$173.98M	-$2.26	N/A	N/A	N/A	N/A	-52.32%	-29.59%	11/6/2025 (Estimated)
NRIX Nurix Therapeutics	-$193.57M	-$2.61	N/A	N/A	N/A	-234.57%	-45.26%	-34.71%	10/10/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.30M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	-$56.42M	$0.24	56.75	38.89	N/A	16.88%	6.93%	3.52%	11/11/2025 (Estimated)

Latest SXTC, TBPH, NRIX, and KURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	KURA Kura Oncology	$0.15	-$0.75	-$0.90	-$0.75	$64.95 million	$15.29 million
7/9/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.79	-$0.52	+$0.27	-$0.52	$16.26 million	$44.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KURA Kura Oncology	0.02	6.16	6.16
NRIX Nurix Therapeutics	N/A	6.82	6.82
SXTC China SXT Pharmaceuticals	0.01	3.54	3.40
TBPH Theravance Biopharma	N/A	6.70	6.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KURA Kura Oncology	N/A
NRIX Nurix Therapeutics	N/A
SXTC China SXT Pharmaceuticals	5.02%
TBPH Theravance Biopharma	99.10%

Insider Ownership

Company	Insider Ownership
KURA Kura Oncology	6.40%
NRIX Nurix Therapeutics	7.40%
SXTC China SXT Pharmaceuticals	3.95%
TBPH Theravance Biopharma	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KURA Kura Oncology	130	86.80 million	81.24 million	Optionable
NRIX Nurix Therapeutics	300	76.45 million	70.79 million	Optionable
SXTC China SXT Pharmaceuticals	90	116.03 million	111.45 million	Not Optionable
TBPH Theravance Biopharma	110	50.36 million	46.89 million	Optionable

SXTC, TBPH, NRIX, and KURA Headlines

Recent News About These Companies

Invesco Ltd. Sells 23,515 Shares of Theravance Biopharma, Inc. $TBPH

September 10 at 3:02 AM | marketbeat.com

Q3 Earnings Estimate for TBPH Issued By Zacks Research

September 7 at 6:50 AM | marketbeat.com

Theravance Biopharma, Inc. $TBPH Shares Bought by PDT Partners LLC

September 6, 2025 | marketbeat.com

Research Analysts Set Expectations for TBPH Q3 Earnings

September 6, 2025 | americanbankingnews.com

Theravance Biopharma (NASDAQ:TBPH) Hits New 12-Month High - Should You Buy?

September 4, 2025 | marketbeat.com

Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 2, 2025 | prnewswire.com

Wellington Management Group LLP Sells 43,062 Shares of Theravance Biopharma, Inc. $TBPH

September 2, 2025 | marketbeat.com

Russell Investments Group Ltd. Has $429,000 Stake in Theravance Biopharma, Inc. $TBPH

September 2, 2025 | marketbeat.com

Vanguard Group Inc. Grows Stake in Theravance Biopharma, Inc. $TBPH

September 1, 2025 | marketbeat.com

Theravance Biopharma, Inc. $TBPH Shares Sold by Deutsche Bank AG

September 1, 2025 | marketbeat.com

Nuveen LLC Acquires Shares of 374,952 Theravance Biopharma, Inc. $TBPH

August 30, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above 50 Day Moving Average - Here's Why

August 28, 2025 | marketbeat.com

Theravance Biopharma, Inc.: Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic ...

August 25, 2025 | finanznachrichten.de

Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple ...

August 25, 2025 | finance.yahoo.com

Theravance Biopharma completes enrollment in CYPRESS study

August 25, 2025 | msn.com

Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy

August 25, 2025 | prnewswire.com

Theravance Biopharma Settles Patent Dispute with Cipla

August 20, 2025 | msn.com

Theravance Biopharma (NASDAQ:TBPH) Hits New 1-Year High - Here's What Happened

August 20, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Rating Increased to Strong-Buy at Wall Street Zen

August 17, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Stock Price Up 3.4% - Here's Why

August 16, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Sets New 1-Year High on Earnings Beat

August 14, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, TBPH, NRIX, and KURA Company Descriptions

Kura Oncology NASDAQ:KURA

$8.44 +0.44 (+5.43%)

As of 03:05 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Nurix Therapeutics NASDAQ:NRIX

$9.06 -0.15 (-1.58%)

As of 03:04 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.45 -0.03 (-1.69%)

As of 03:04 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Theravance Biopharma NASDAQ:TBPH

$13.61 -0.15 (-1.07%)

As of 03:05 PM Eastern

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SXTC, TBPH, NRIX, and KURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SXTC, TBPH, NRIX, and KURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SXTC, TBPH, NRIX, and KURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, TBPH, NRIX, and KURA Company Descriptions

Kura Oncology NASDAQ:KURA

Nurix Therapeutics NASDAQ:NRIX

China SXT Pharmaceuticals NASDAQ:SXTC

Theravance Biopharma NASDAQ:TBPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SXTC, TBPH, NRIX, and KURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SXTC, TBPH, NRIX, and KURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SXTC, TBPH, NRIX, and KURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, TBPH, NRIX, and KURA Company Descriptions

Kura Oncology NASDAQ:KURA

Nurix Therapeutics NASDAQ:NRIX

China SXT Pharmaceuticals NASDAQ:SXTC

Theravance Biopharma NASDAQ:TBPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools